About Us

Kadmon is a clinical-stage biopharmaceutical company that discovers, develops and delivers transformative therapies for unmet medical needs. We are developing treatments for immune and fibrotic diseases as well as immuno-oncology therapies.

Learn More


We have a deep understanding of the pathways involved in inflammation and fibrosis. Our late-stage product candidate, Belumosudil, is an inhibitor of ROCK2, a signaling pathway that modulates key inflammatory and fibrotic processes. A pivotal study of belumosudil is underway in patients with chronic graft-versus-host disease (cGVHD). A Phase 2 clinical trial of belumosudil is also underway in patients with systemic sclerosis (SSc).

Read More